Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.46 |
| ▸ | CDK1 | P06493 | 3/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | POLA1 | P09884 | 5/20 | 0.42 |
| ▸ | XDH | P47989 | 6/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16146399 | 0.90 | CDK1 (0.41) | ADORA3ADORA2ACDK1CCNB1CCNA2 | |
| SCHEMBL11133893 | 0.83 | CDK1 (0.40) | ADORA3ADORA2ACDK1CCNB1CCNA2 | |
| SCHEMBL1074970 | 0.81 | POLA1 (0.57) | ADORA3ADORA2ACDK1CCNB1CCNA2 | |
| SCHEMBL28299226 | 0.77 | POLA1 (0.53) | ADORA3ADORA2ACDK1CCNB1CCNA2 | |
| SCHEMBL28770511 | 0.77 | PDPK1 (0.42) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL19281406 | 0.77 | CYP1A2 (0.46) | ADORA3ADORA2ACDK1CCNB1CCNA2 | |
| SCHEMBL5466583 | 0.76 | HRH3 (0.35) | ADORA3ADORA2ACDK1CCNB1CCNA2 | |
| SCHEMBL30610405 | 0.76 | CDK1 (0.53) | ADORA3ADORA2ACDK1CCNB1CCNA2 | |
| Hydrochloric Acid SCHEMBL26629016 | 0.74 | CDK1 (0.51) | ADORA3ADORA2ACDK1CCNB1CCNA2 | |
| SCHEMBL16147040 | 0.73 | XDH (0.56) | ADORA3CDK1CCNB1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225303-A1 | 8-Oxoadenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1728792-A1 | 8-OXOADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-06 | — | — | EP | disclosed |
| WO-2002085904-A1 | SNYTHESIS AND METHODS OF USE OF PURINE ANALOGUES AND DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20020156277-A1 | Synthesis and methods of use of purine analogues and derivatives | NEO THERAPEUTICS, INC. | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156277-A1 | Synthesis and methods of use of purine analogues and derivatives | SLC29A1, ATIC, PNP | ADORA3 9/4885ADORA2A 4/4885CDK1 1103/4885 |
| US-20070225303-A1 | 8-Oxoadenine Compound | TLR7, CCR8, TLR8 | ADORA3 34/4885ADORA2A 22/4885CDK1 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.